Eventide Asset Management LLC Purchases 88 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Eventide Asset Management LLC lifted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 188,412 shares of the company’s stock after acquiring an additional 88 shares during the period. IDEXX Laboratories makes up about 1.6% of Eventide Asset Management LLC’s portfolio, making the stock its 13th largest holding. Eventide Asset Management LLC owned approximately 0.23% of IDEXX Laboratories worth $95,190,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in IDXX. B. Riley Wealth Advisors Inc. raised its holdings in shares of IDEXX Laboratories by 35.8% during the 1st quarter. B. Riley Wealth Advisors Inc. now owns 1,879 shares of the company’s stock worth $1,015,000 after buying an additional 495 shares in the last quarter. Tidal Investments LLC lifted its holdings in shares of IDEXX Laboratories by 71.4% in the first quarter. Tidal Investments LLC now owns 4,373 shares of the company’s stock worth $2,361,000 after acquiring an additional 1,821 shares during the last quarter. Hancock Whitney Corp acquired a new stake in shares of IDEXX Laboratories in the 1st quarter valued at approximately $220,000. LRI Investments LLC bought a new stake in shares of IDEXX Laboratories during the 1st quarter valued at approximately $57,000. Finally, Swedbank AB acquired a new position in IDEXX Laboratories during the 1st quarter worth approximately $21,013,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Stock Up 1.1 %

IDEXX Laboratories stock opened at $421.76 on Friday. The firm has a 50 day moving average price of $453.61 and a two-hundred day moving average price of $478.67. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $583.39. The firm has a market cap of $34.54 billion, a price-to-earnings ratio of 40.67, a PEG ratio of 3.68 and a beta of 1.36.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, topping analysts’ consensus estimates of $2.69 by $0.11. The business had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. IDEXX Laboratories’s quarterly revenue was up 6.6% on a year-over-year basis. During the same quarter last year, the firm earned $2.53 earnings per share. Equities analysts predict that IDEXX Laboratories, Inc. will post 10.43 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on IDXX. Piper Sandler restated a “neutral” rating and issued a $435.00 target price (down previously from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Stifel Nicolaus lowered their target price on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a report on Thursday, October 10th. JPMorgan Chase & Co. reduced their price target on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Barclays dropped their price objective on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Finally, StockNews.com raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Thursday. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $552.38.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.